Comparative effects of metformin and pioglitazone on lipid profile of rabbits

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 2, 2015, Pages 553-555

  Khan, Rafeeq Alam ^a   Baig, Sadia Ghousia ^a   Siddiq, Afshan ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Cholesterol; Diabetes mellitus; Lipoproteins; Metformin; Pioglitazone

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; WATER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; COMPARATIVE STUDY;

ANIMALS; FEMALE; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; RABBITS; THIAZOLIDINEDIONES;

EID: 84925014484     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Betteridge DJ (2007). Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes. Metab., 9(5): 640-647.
2. Davidson M, Meyer PM, Haffner S, Feinstein S, Sr RD, Kondos GT, Perez A, Chen Z and Mazzone T (2008). Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid in tima media thickness progression in patients with type 2 diabetes Mellitus. Circulation, 117: 2123-2130.
3. Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N and Ersoz HO (2014). Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 122(5): 295-302.
4. Petersen JL and McGuire DK (2005). Impaired glucose tolerance and impaired fasting glucose a review of diagnosis, clinical implications and management. Diabetes Vasc. Dis. Res., 2(1): 09-15.
5. Qin ZY, Zhang M, Dai YM, Wang YM, Zhu GZ, Zhao YP, Ji CB, Qiu J, Cao XG and Guo XR (2014). Met formin prevents LYRM1-induced insulin resistance in 3T3-L1 adipocytes via a mitochondrial-dependent mechanism. Exp Biol. Med. (Maywood) (ahead of print).
6. Quinn CE, Hamilton PK, Lockhart CJ and McVeigh GE (2008). Thiazolidinediones: Effects on insulin resistance and the cardiovascular system. Br. J. Pharmacol., 153(4): 636-645.
7. Rojas LBA and Gomes MB (2013). Metformin: An old but still the best treatment for type 2 diabetes. Diabetol. & Metab. Syndr., 5: 6.
8. Sangeeta S (2012). Metformin and pioglitazone in polycystic ovarian syndrome: A comparative study. J. Obstet. Gynaecol. India, 62(5): 551-556.
9. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M and Cantley LC (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310(5754): 1642-1646.
10. Yuka S, Toru M, Hiroki O, Yoko N, Yuko O, Kazufumi N, Yukihiro S, Kazuhiro O, Hiroshi M, Kunihisa K, Hiroshi I (2014). Pioglitazone prevents the endothelial dysfunction induced by ischemia and reperfusion in healthy subjects. J Cardiovasc Pharmacol. (ahead of print).
11. Zhang L, Qiao Q, Tuomilehto J, Hammar N, Janus ED, Söderberg S, Mohan V, Ramachandran A, Dong YH, Lam TH and Pang ZC (2009). Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: The DECODA study. Diabetes Metab. Res Rev., 25(6): 549-557.
12. Zhang M, Qin ZY, Dai YM, Wang YM, Zhu GZ, Zhao YP, Ji CB, Zhu JG, Shi CM, Qiu J, Cao XG and Guo XR (2014). Knockdown of LYRM1 rescues insulin resistance and mitochondrial dysfunction induced by FCCP in 3T3-L1 Adipocytes. Cell Biochem. Biophys., 70(1): 667-675.